In what has been an unusual year for the MedTech industry, Micromate™ performed substantially well: unveiled to the world in Spring 2020, it obtained its CE-Mark in early Summer, and started its clinical use in early Fall. The first ever Micromate™ user has been Dr. Marco van Strijen at the St. Antonius Ziekenhuis, in Nieuwegein, The Netherlands.
The highest accuracy with no complications
Nine months have passed since that first installation, and the clinical results obtained with the system by the reference sites in The Netherlands, Austria, and Switzerland are remarkable. Quickly approaching 100 procedures, Micromate™ has confirmed its capability of supporting submillimeter accuracy from head to toe.
In the reported cases, Micromate™ supported 0.43 ± 0.5mm average accuracy of alignment to the trajectory and 0.79 ± 0.41º average angular accuracy of needle guidance from entry to target location.
These results are based on reported data from procedures conducted in 10 body regions, some particularly critical: Femur, Liver, Thoracic Spine, Lumbar Spine, Aorta, Lung, Ovaries, Ilium-sacrum, Sternum, and the Parotid Gland. No complications have been reported, and a 100% diagnostic yield and accuracy have been attained on biopsy procedures.
A modular surgical platform for minimally invasive surgery
Micromate™ was not limited to Europe. This versatile, modular surgical platform was also adopted by strategic partners looking to support robotic-guided procedures for different applications.
On March 22nd, 2021, Dr. Kevin Foley, at Baptist Memorial Hospital, in Memphis, TN, completed the first spine fusion procedure using Micromate™.
Integrated into the Fusion Robotics system – which also includes a navigation station and an instrument set – Micromate™ assisted on the execution of a single-level minimally invasive transforaminal lumbar interbody fusion (MI-TLIF), including the placement of pedicle screw fixation guided by the robot.
Several more surgeries took place since that day, all with 100% accuracy and no reported pedicle breach events. The one-month follow-up appointments with the patients confirmed the successful outcomes.
What will the next 9 months bring?
Innovation is at the core of our strategy, as it is making our cutting-edge technology available everywhere, for as many applications as possible.
Over the next 9 months, along with installing more reference sites in Europe and expanding to other key geographies, we are going to launch our full-fledged surgical platform. When it happens, Micromate™ users will also be able to achieve the same reported submillimeter accuracy under CT, Ultrasound, and/or Optical Navigation guidance. All in one platform.
If you want to be part of the next chapter, contact us today.
